» Articles » PMID: 29365407

[Efficacy and Safety of Recombinant Human Thrombopoietin Combined with Hormonal and Cyclosporine in 20 Patients with Newly Diagnosed Immune-related Pancytopenia]

Overview
Specialty Hematology
Date 2018 Jan 25
PMID 29365407
Authors
Affiliations
Soon will be listed here.
References
1.
Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View

2.
Kirshenbaum A, Akin C, Goff J, Metcalfe D . Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117)low/ MPL(CD110)+ human mast cells from hematopoietic progenitor cells. Exp Hematol. 2005; 33(4):413-21. DOI: 10.1016/j.exphem.2004.12.005. View

3.
de Graaf C, Metcalf D . Thrombopoietin and hematopoietic stem cells. Cell Cycle. 2011; 10(10):1582-9. PMC: 3127159. DOI: 10.4161/cc.10.10.15619. View

4.
Zeigler F, De Sauvage F, Widmer H, Keller G, Donahue C, Schreiber R . In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994; 84(12):4045-52. View

5.
Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G . Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy. Biomed Res Int. 2015; 2015:597293. PMC: 4377357. DOI: 10.1155/2015/597293. View